Research Team

The Pacific Northwest (PNW) Prostate Cancer SPORE aims to focus on finding molecular and other factors associated with the risk of prostate cancer recurrence and progression as well as its response – and resistance – to treatment. In 2002, the NCI awarded Fred Hutch $12.7 million to lead a multi-center, multi-project, five-year investigation into the genetic mechanisms of prostate cancer progression, and most recently in 2018 renewed the SPORE through 2023. 

Our Funding Timeline

+

2018

The NCI renews the PNW Prostate Cancer SPORE through 2023. This iteration of the project is led by Drs. Peter S. Nelson, Janet L. Stanford, and Dan W. Lin. This continuing 5-year, $11.14M award will support the exceptional resources and infrastructure created by the SPORE and the continued efforts to translate groundbreaking basic science research to clinical therapies.

2013

The PNW Prostate Cancer SPORE is awarded an $11.3 million, five-year competitive grant renewal for its continued leadership of a multi-center prostate cancer research consortium whose collective goal is to reduce the morbidity and mortality associated with prostate cancer. This continuation represents a coordinated effort between four institutions, each with established programs and strengths in translational prostate cancer research.

2006

NCI renews the PNW Prostate Cancer SPORE grant under the direction of Dr. Peter Nelson, PI, and co-PIs, Drs. Janet Stanford and Paul Lange. A new five-year, $11.8 million grant was awarded to further the PNW SPORE’s aim to address fundamental questions underlying prostate cancer risk, prognosis, and therapeutic response, reinforcing the reputation of the Pacific Northwest consortium as a major force in prostate cancer research.

2002

NCI awards Fred Hutchinson Cancer Research Center $12.7 million to lead a multi-center, multi-project, five-year investigation into the genetic mechanisms of prostate cancer progression. Understanding how and why prostate cancer can turn deadly is key to developing therapies that may effectively treat men with recurrent or advanced prostate cancer, for which there is no cure. Under the direction of Principal Investigator (PI) Paul Lange, MD, and co-PIs Janet Stanford, PhD, and Peter Nelson, MD, the initiative involved more than 50 investigators from four institutions in Seattle and Vancouver, BC.

Prostate SPORE Leadership

Dr. Peter Nelson

Pete Nelson, M.D., Principal Investigator

Dr. Pete Nelson is co-director of Core A (Leadership & Administration) of the PNW Prostate Cancer SPORE and co-leader of Project 4 (Clinical Development of Therapeutic Strategies Targeting DNA Damage Repair). Dr. Nelson is a full member of Fred Hutch, a professor in the University of Washington Medical School’s Medical Oncology Division, an adjunct professor in the UW’s Departments of Genome Sciences and Pathology, co-head of the Cancer Center’s Program in Prostate Cancer Research (PPCR), and Director of the Canary Foundation Prostate Cancer Program.

The focus of Dr. Nelson’s current work (in the Nelson Lab at Fred Hutch) involves efforts to understand the process of prostate carcinogenesis with an aim toward developing diagnostic, prognostic, and therapeutic strategies. The major projects of the Nelson Lab are molecular analysis of therapies for early and late stage prostate carcinoma, characterization of the prostate androgen-response program, analysis of prostate serine protease function in metastatic prostate carcinoma, determining the role of damage responses in the tumor microenvironment that promote cancer growth and resistance to therapy. For more information about the Nelson Lab’s work, visit the Nelson lab site

Dr. Janet Stanford

Janet Stanford, Ph.D., Co-Principal Investigator

Dr. Janet Stanford is a co-director of Core A (Leadership & Administration) of the PNW Prostate Cancer SPORE, a co-leader of Project 1 (Molecular Predictors of Prostate Cancer Progression and Mortality), and co-head of the Program in Prostate Cancer Research (PPCR). Dr. Stanford is a member of Fred Hutch and a research professor of epidemiology at the University of Washington’s School of Public Health. In the early 1990s, Stanford became one of the first Center researchers to focus on prostate cancer and today is recognized worldwide as an expert in the field. Her numerous studies and leadership of the program in prostate cancer research have illuminated many of the environmental, behavioral and genetic factors that can cause the disease. She also helps lead a nationwide research project of more than 2,000 people in more than 300 families exploring why prostate-cancer risk is higher in some families. Understanding the inherited genetic mutations for prostate cancer may provide new clues to help diagnose, treat, cure and even prevent it in future generations.

Dr. Stanford’s main research interests focus on hormonal, environmental, lifestyle and genetic factors that may alter cancer risk, cancer recurrence or progression, and cancer-specific mortality. The role of underlying genetic susceptibility based on rare, and high penetrance mutations as well as more common genetic variants of lower penetrance is a major focus of her research. As a cancer epidemiologist, Dr. Stanford has been involved in the development, implementation, and analyses of research studies of the etiology and progression of several different types of cancer. However, her current concentration is on prostate cancer. The recent completion of two large population-based case-control studies of risk factors for prostate cancer has allowed Dr. Stanford and her research team to examine environmental/lifestyle exposures and genetic polymorphisms in candidate genes in relation to prostate cancer etiology and outcomes.

Dr. Daniel Lin

Daniel Lin, M.D., Co-Principal Investigator

Dan Lin is co-director of Core A (Leadership & Administration) of the PNW Prostate Cancer SPORE, a member of the SPORE Executive Committee. He is a Professor of Urology at the University of Washington School of Medicine, Chief of Urologic Oncology, and a urologist specializing in genitourinary oncology, prostate cancer early detection and prevention. Dr. Lin’s research currently focuses on the molecular mechanisms of prostate carcinogenesis and biomarkers of prostate cancer progression. In addition to his SPORE research, Dr. Lin is co-PI on a nationwide phase III clinical trial administered through the VA Puget Sound Healthcare System investigating the efficacy of adjuvant chemotherapy to prevent progression in patients at high risk for relapse after radical prostatectomy; PI on a multi-institutional study (through the Canary Foundation) to discover and confirm biomarkers that predict aggressive disease in a prospective cohort of men on active surveillance; co-investigator on a study investigating the synergistic targeting of androgen receptor and androgen metabolism in prostate cancer; PI on a project to use an in vivo human intervention model to evaluate the mechanisms underlying the associations of sulforaphane and Brassica vegetables with reduced prostate cancer risk; co-investigator on a multi-center, retrospective tissue microarray (TMA) study to evaluate tissue biomarkers for their ability to predict recurrent prostate cancer at the time of radical prostatectomy (RP), and co-PI on a project to model active surveillance strategies to optimize outcomes and patient decision-making.

Researchers & Clinicians

Joshi Alumkal

Joshi Alumkal, M.D.

Eva Corey

Eva Corey, Ph.D.

Mads Daugaard

Mads Daugaard, Ph.D.

Ruth Etzioni

Ruth Etzioni, Ph.D.

Joshi Alumkal, M.D.

Joshi Alumkal is co-leader of Project 2 (Targeting Emergent Vulnerabilities in AR-Inactive Prostate Cancer). Dr. Alumkal received his MD from Baylor College of Medicine, completed his Internal Medicine residency training at UT Southwestern Medical Center, and completed his Medical Oncology fellowship training at Johns Hopkins University. He was appointed as an Assistant Professor in the Department of Medicine at OHSU in 2007 and Molecular and Medical Genetics in 2010. He was named Co-Leader of the OHSU Prostate Cancer Research Program in 2012.Dr. Alumkal is now the Leader of the Prostate/Genitourinary Medical Oncology Section and Associate Division Chief for Basic Research in the Hematology-Oncology Division and Professor with tenure in the Department of Internal Medicine. Dr. Alumkal is also a member of the University of Michigan Rogel Cancer Center and Director of Epigenetic Therapy in the Michigan Center for Translational Pathology. Dr. Alumkal’s main goal is to link laboratory and clinical scientists in order to develop more effective treatments for patients with advanced cancers, including men with prostate cancer whom he treats.

Martin Gleave

Martin Gleave, M.D.

John Gore

John L. Gore, M.D.

Bruce Montgomery

Bruce Montgomery, M.D.

Colm Morrissey

Colm Morrissey, Ph.D.

Colin Pritchard

Colin Pritchard, M.D., Ph.D.

Lawrence True

Lawrence True, M.D.

Evan Yu

Evan Yu, M.D.